Wegovy injection before and after: what actually changes, and why

What is your body doing differently in the weeks before noticeable change?

The first injection arrives at 0.25mg, a dose that exists purely to let your system adjust, not to produce rapid weight loss. This catches people out. The expectation is often that week one will feel dramatic; the reality is more like a quiet recalibration. Semaglutide binds to GLP-1 receptors in the gut and brain, slowing how quickly food leaves your stomach and dampening appetite signals. But at 0.25mg, that effect is gentle. What you may notice is that a smaller portion feels like enough, or that the urge to snack between meals loosens its grip a little.

Nausea shows up for some people at this stage, usually after eating too quickly or too much. It tends to ease within a week or two as the body settles. The NHS semaglutide medicine guide describes these gastrointestinal effects as common and generally short-lived, though they can return briefly after each dose increase.

The honest before-and-after picture in the early weeks, then, is less about weight and more about relationship with food. Hunger stops feeling urgent for many people. That shift is worth noting because it often persists long after the scales catch up.

After the titration: what does the evidence show at maintenance dose?

Once a prescriber has moved someone up to the 1.7mg or 2.4mg maintenance dose, the weight-loss trajectory tends to steepen. The STEP 1 trial (1,961 adults with obesity or overweight and at least one weight-related condition) found that participants on 2.4mg lost an average of around 15% of body weight over 68 weeks. Those who reached the full dose and stayed on treatment consistently saw the largest changes. The people who lost the least were those who stopped early or never reached the maintenance dose.

There is a misconception worth addressing gently here: that the pen does the work and lifestyle barely matters. The trial ran alongside a reduced-calorie diet and increased physical activity for every participant. The injection lowers appetite significantly, which makes those lifestyle adjustments more achievable, but it does not replace them. Strength training, adequate protein and staying well hydrated all matter more, not less, on treatment.

For a fuller look at how weight-loss injection results compare across the people who have used them, the documented weight-loss injection results page covers individual variation in more depth.

What should you check before each injection, and does preparation change anything?

Before every injection, a few practical checks make a real difference. Wegovy pens are stored in the fridge; injecting a cold pen can sting more than necessary. There is a specific window for letting the pen come to room temperature before use, the exact duration is in your Patient Information Leaflet and varies by pen type, so always check there rather than relying on a general rule. If you want to read more about that, the guide on how long to leave Wegovy out before injecting goes through what the guidance actually says.

Injection site matters too. Abdomen, thigh and upper arm are all licensed sites; rotating between them reduces the chance of localised skin changes building up in one spot. Cleaning the site beforehand is straightforward, alcohol swabs are the standard approach. Whether you eat before or after injecting is a separate question from dose timing, the practical guide on eating around your injection covers what the evidence and the SmPC actually say.

Proper storage matters at every stage, not just the hour before you inject. A pen that has been left out too long or exposed to heat may no longer be effective. The Wegovy storage guide on this site covers fridge conditions, travel and what to do if you are unsure whether a pen is still viable.

Is Wegovy right for you, and what happens at the consultation?

The before-and-after question ultimately starts with eligibility. Wegovy is licensed in the UK for adults with a BMI of 30 or above, or 27 to 29.9 with at least one weight-related condition such as high blood pressure, high cholesterol or type 2 diabetes. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. The prescriber assesses the whole picture (medical history, other medicines you take, your goals) before any treatment is issued.

At nume, a GPhC-registered prescriber reads every consultation personally the same day. There is no algorithm making that call. The Wegovy treatment overview sets out the eligibility criteria and what the assessment covers. If you have questions about how cost factors into the decision, the Wegovy cost guide explains what a legitimate price actually includes, and why the lowest listing is rarely the right measure for a prescription medicine.

The full treatment landscape, including how Wegovy compares to other approaches, is covered on the weight-loss treatment options page. When you are ready, speaking to our prescribers is the natural next step, a free consultation, reviewed the same day.